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Abstract
Strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection were evaluated for the ability to
elicit protective immunity against wild-type SIVmac239 infection of rhesus macaques by two different vaccine regimens. Six
animals were inoculated at 8-week intervals with 6 identical doses consisting of a mixture of three different envelope
variants of single-cycle SIV (scSIV). Six additional animals were primed with a mixture of cytoplasmic domain-truncated
envelope variants of scSIV and boosted with two doses of vesicular stomatitis virus glycoprotein (VSV G) trans-
complemented scSIV. While both regimens elicited detectable virus-specific T cell responses, SIV-specific T cell frequencies
were more than 10-fold higher after boosting with VSV G trans-complemented scSIV (VSV G scSIV). Broad T cell recognition
of multiple viral antigens and Gag-specific CD4
+ T cell responses were also observed after boosting with VSV G scSIV. With
the exception of a single animal in the repeated immunization group, all of the animals became infected following an
intravenous challenge with SIVmac239. However, significantly lower viral loads and higher memory CD4
+ T cell counts were
observed in both immunized groups relative to an unvaccinated control group. Indeed, both scSIV immunization regimens
resulted in containment of SIVmac239 replication after challenge that was as good as, if not better than, what has been
achieved by other non-persisting vaccine vectors that have been evaluated in this challenge model. Nevertheless, the extent
of protection afforded by scSIV was not as good as typically conferred by persistent infection with live, attenuated SIV.
These observations have potentially important implications to the design of an effective AIDS vaccine, since they suggest
that ongoing stimulation of virus-specific immune responses may be essential to achieving the degree of protection
afforded by live, attenuated SIV.
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Introduction
The search for a safe and effective AIDS vaccine continues.
While live, attenuated strains of SIV afford reliable long-term
protection in animal models, at least against closely related
challenge viruses, they have the potential to regain a pathogenic
phenotype through the accumulation of compensatory genetic
changes over prolonged periods of persistent replication in vivo [1–
7]. Hence, there are legitimate safety concerns with the use of live,
attenuated HIV-1 as a vaccine approach in people. Vaccine
candidates based on recombinant DNA and/or viral vectors are
safer and elicit potent cellular immune responses that effectively
control virus replication after challenge with the simian-human
immunodeficiency virus chimera SHIV89.6P [8–11]. However,
these vaccines afford only modest protection against SIV challenge
strains, such as SIVmac239 and SIVmac251, that express neutral-
ization-resistant, CCR5-tropic envelope glycoproteins typical of
most primary HIV-1 field isolates [12–17].
The predictive validity of the more rigorous SIV challenge
model as an indicator of vaccine efficacy in humans was recently
supported by the failure of a replication-defective, recombinant
adenovirus type 5 (rAd5) vaccine candidate to protect against
HIV-1 infection in a high profile clinical trial [18–23]. In a phase
IIb proof-of-concept trial, nearly 3000 participants were immu-
nized at 0, 1 and 6 months with rAd5 vectors expressing HIV-1
clade B gag, pol and nef genes, or a placebo control [18,19]. The
trial was halted after the data safety monitoring board, at its first
interim analysis, determined that the vaccine not only failed to
prevent infection, but failed to reduce viral loads in immunized
individuals who later became infected [18,19]. These disappoint-
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approaches might provide better protection in future trials
[18,19,24]. Thus, there is an urgent need to continue to pursue
innovative vaccine concepts that may afford more promising safety
and efficacy profiles.
It is presently unclear whether persistent, low-level virus
replication, and associated stimulation of virus-specific immune
responses, is a prerequisite for the robust protection afforded by
infection of animals with live, attenuated strains of SIV. As an
experimental AIDS vaccine approach designed to uncouple
immune activation from ongoing virus replication and turnover
of CD4
+ lymphocytes, we and others have developed genetic
systems for producing strains of SIV that are limited to a single
cycle of infection [25–27]. Our approach is based on a two-
plasmid system for producing Gag-Pol-complemented SIV with
mutations in a cis-acting sequence required for ribosomal
frameshifting between the gag and pol reading frames [25,26].
One plasmid carries a full-length proviral genome with mutations
in the gag-pol-frameshift site to prevent Pol translation, and a
second plasmid carries a Gag-Pol-expression construct that also
has mutations in the frameshift site [25,26]. Co-transfection of
both plasmids into the same cells results in the release of Gag-Pol-
complemented virus particles that package a pol-deficient viral
genome. Cells infected with this virus express all of the viral gene
products except Pol and release immature virions that cannot
complete subsequent rounds of infection [25,26]. Since neither
construct retains a functional frameshift site, high-titer stocks of
single-cycle SIV (scSIV) can be produced without generating
replication-competent virus through recombination [25,26].
In preliminary studies, viral RNA loads reflecting the produc-
tion of non-infectious progeny virus by scSIV-infected cells were
measurable in plasma after inoculation of macaques with
concentrated doses of scSIV [27–29]. Progressive reductions in
these transient peaks of viremia were observed after three
successive doses, and the rank order of peak viral loads after the
last dose of scSIV was the same as the rank order of peak viral
loads after challenge [28]. These observations suggested that
protective immunity might improve with repeated immunization
and that the ability to contain scSIV infection after repeated
immunizations might ultimately be predictive of the ability to
contain wild-type SIV infection after challenge; a hypothesis we
have termed ‘‘immunization to extinction.’’
Protective immunity may also be improved by maximizing the
stimulation of virus-specific T cell responses. While a number of
factors can influence the development of T cell memory, results
from murine systems indicate that the size of the memory T cell
population is ultimately determined by the number of activated T
cells driven to proliferate during the process of clonal expansion
[30,31]. All other factors being equal, the magnitude of antigen
presentation largely determines the extent of T cell activation.
Thus, we reasoned that approaches designed to maximize the
infectivity of scSIV, and the frequency of scSIV-infected antigen
presenting cells in immunized animals, should increase both the
size and longevity of the memory T cell population.
In the present study, we compared two different immunization
regimens with scSIV for the ability to contain virus replication
after an intravenous challenge with SIVmac239. One group of
animals was inoculated with six identical doses of the same
cryopreserved stocks of scSIV to determine if repeated immuni-
zation would promote the maturation of virus-specific immune
responses. A second group of animals was primed with scSIV
strains expressing envelope glycoproteins with truncated cytoplas-
mic tails and boosted with VSV G trans-complemented scSIV to
maximize infection, antigen presentation and the stimulation of
virus-specific T cell responses. Despite differences in the
magnitude of virus-specific T cell responses elicited, both
immunization regimens resulted in statistically significant reduc-
tions in viral loads and better preservation of memory CD4
+ T cell
subsets after challenge compared to unimmunized control animals.
Results
Repeated versus prime and boost immunizaton with
single-cycle SIV
Rhesus macaques were immunized with single-cycle SIV by two
different vaccine regimens to compare the effects of frequency of
inoculation versus infectious dose of the inoculum on the
development of protective immunity. One group of animals
(Group A) was repeatedly immunized with the same dose of scSIV
to determine if mimicking persistent infection through repeated
antigenic stimulation would lead to the progressive maturation of
virus-specific immune responses and incremental reductions in
single-cycle viral loads predictive of the ability to contain wild-type
SIV replication after challenge. A second group of animals (Group
B) was immunized by a prime and boost regimen designed to
maximize scSIV infection, antigen presentation and the stimula-
tion of virus-specific T cell responses to determine if higher overall
T cell responses might result in better control of SIV infection after
challenge.
Three different envelope variants of single-cycle SIV expressing
full-length (TMopen) or truncated (TMstop) forms of the 239, 316
and 155T3 envelope glycoproteins were used for immunization
[32]. The 239 envelope uses CCR5 as a co-receptor for infection
of predominantly memory CD4
+ T cells [32,33]. The 316
envelope also uses CCR5, but differs from the 239 envelope by
6 amino acids in gp120 which result in a 50- to 100-fold
enhancement in infectivity for primary macrophages in culture
[25,32,34]. The 155T3 envelope, which differs from the 239
envelope by 22 amino acids in gp120, uses CXCR4 rather than
CCR5 as a co-receptor for infection of both naive and memory
CD4
+ T lymphocytes [32,33]. These three envelopes were selected
Author Summary
AIDS vaccine candidates based on recombinant DNA and/
or viral vectors stimulate potent cellular immune respons-
es. However, the extent of protection achieved by these
vaccines has so far been disappointing. While live,
attenuated strains of SIV afford more reliable protection
in animal models, there are justifiable safety concerns with
the use of live, attenuated HIV-1 in humans. As an
experimental vaccine approach designed to uncouple
immune activation from ongoing virus replication, we
developed a genetic system for producing strains of SIV
that are limited to a single cycle of infection. We compared
repeated versus prime-boost vaccine regimens with single-
cycle SIV for the ability to elicit protective immunity in
rhesus macaques against a strain of SIV that is notoriously
difficult to control by vaccination. Both vaccine regimens
afforded significant containment of virus replication after
challenge. Nevertheless, the extent of protection achieved
by immunization with single-cycle SIV was not as good as
the protection typically provided by persistent infection of
animals with live, attenuated SIV. These observations have
important implications for the design of an effective AIDS
vaccine, since they suggest that ongoing stimulation of
virus-specific immune responses may ultimately be neces-
sary for achieving the robust protection afforded by live,
attenuated SIV.
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cells by scSIV and to potentially broaden envelope-specific
antibody responses. For each of these envelope variants, TMstop
strains of scSIV were created by introducing a glutamic acid to
stop-codon change at position 767 (E767*) in the gp41 cytoplasmic
tail. The E767* mutation was present in the original isolate of
SIVmac316 and may represent a naturally selected change to
facilitate virus replication in macrophage [34]. Truncation of the
gp41 cytoplasmic tail at this position was also shown to increase
envelope glycoprotein incorporation into virions and to enhance
virus infectivity [32,35,36]. To facilitate the stimulation of virus-
specific CD8
+ T cell responses, mutations in nef that eliminate
residues required for MHC class I downregulation were also
included in each strain [28,37,38].
In Group A, six animals were immunized intravenously at 8-week
intervals with 6 identical doses of the same cryopreserved stocks of
scSIV. Each dose contained a mixture of three scSIV strains
expressing full-length envelope glycoproteins, scSIVmac239 TMopen,
scSIVmac316 TMopen and scSIVmac155T3 TMopen (Figure 1A) [32].
In Group B, six additional animals were primed intravenously
with a mixture of the envelope cytoplasmic tail-truncated strains,
scSIVmac239 TMstop,s c S I V mac316 TMstop and scSIVmac155T3
TMstop. The animals in Group B were then boosted intravenously
with scSIV trans-complemented with the vesicular stomatitis virus
glycoprotein (VSV G) on weeks 12 and 24 (Figure 1B). Although it
would have been possible to trans-complement any of the three
envelope variants of scSIV with VSV G, only scSIVmac239 TMopen
was used for these booster inoculations. The selection of scSIVmac239
TMopen was based on an effort to focus strain-specific antibody
responses on the envelope glycoprotein of SIVmac239. However, to
prevent neutralization of the second boost by VSV G-specific
antibodies, two different serotypes of VSV G were used for each
inoculation [39]. The first boost was trans-complemented with the
Indiana serotype of VSV G (VSV GI scSIV) and the second boost
was trans-complemented with the New Jersey serotype of VSV G
(VSV GNJ scSIV).
Plasma viral RNA loads were detectable after each dose
of single-cycle SIV
Plasma viral RNA loads were measured independently for each
envelope variant of scSIV using a quantitative, multiplex, real-time
RT-PCR assay specific for unique sequence tags cloned into the
pol-locus of each strain [32]. Measurable levels of virion-associated
viral RNA were transiently detectable in plasma after each dose
(Figure 2). Since SIV particles are rapidly cleared from plasma
with an estimated half-life of a few minutes [40–42], these viral
load measurements reflect the ongoing release of non-infectious
particles from scSIV-infected cells.
In Group A, viral loads peaked on day 4 after the first
inoculation and declined below the limit of detection (,30 RNA
Figure 1. Rhesus macaques were immunized with single-cycle SIV by two different regimens. (A) Six animals in Group A were inoculated
with 6 identical doses of scSIV at 8-week intervals. Each dose consisted of a mixture of scSIVmac239 TMopen, scSIVmac316 TMopen, and scSIVmac155T3
TMopen (5 mg p27 eq. each). (B) Six animals in Group B were primed with a mixture of scSIVmac239 TMstop, scSIVmac316 TMstop, and scSIVmac155T3
TMstop (5 mg p27 eq. each) and boosted on weeks 12 and 24 with VSV G trans-complemented scSIV (10 and 13 mg p27 eq., respectively). Single-cycle
SIVmac239 TMopen was trans-complemented with the Indiana serotype of VSV G for the first boost (week 12) and the New Jersey serotype of VSV G for
the second boost (week 24). (A,B) Twelve weeks after the last dose of scSIV, Groups A and B and four unvaccinated control animals were challenged
intravenously (i.v.) with SIVmac239.
doi:10.1371/journal.ppat.1000272.g001
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PLoS Pathogens | www.plospathogens.org 3 January 2009 | Volume 5 | Issue 1 | e1000272Figure 2. Viral RNA loads were detectable in plasma after each dose of single-cycle SIV. (A) Animals in Group A were inoculated with 6
identical doses of the same cryopreserved stocks of scSIVmac239 TMopen, scSIVmac316 TMopen, and scSIVmac155T3 TMopen at 8-week intervals. (B)
Animals in Group B were primed with a mixture of scSIVmac239 TMstop, scSIVmac316 TMstop, and scSIVmac155T3 TMstop and boosted with VSV G trans-
complemented scSIVmac239 TMopen on weeks 12 and 24. Viral loads were measured independently for each strain of scSIV using a quantitative
multiplex real-time RT-PCR assay specific for unique sequence tags (ggr, cao, and gsa) engineered into each viral genome [32]. The threshold of
detection for this assay was 30 RNA copy eq./ml (dotted line).
doi:10.1371/journal.ppat.1000272.g002
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peak viral loads after the first dose were 1.34610
4, 1.49610
3 and
1.48610
4 RNA copy eq./ml for scSIVmac239, scSIVmac316 and
scSIVmac155T3 respectively. After the second dose, peak viral
loads occurred on day 2 and were 40-fold lower for scSIVmac239
(P=0.001), 25-fold lower for scSIVmac316 (P,0.001) and 50-fold
lower for scSIVmac155T3 (P,0.001) (Figure 2A). Since the inocula
were identical for each dose (same volume of the same
cryopreserved stocks), the lower peak and more rapid clearance
of viremia after the second inoculation almost certainly reflects the
elimination of scSIV-infected cells by virus-specific immune
responses. Further reductions in peak viremia were also observed
after the fifth and sixth inoculations for scSIVmac316 (P=0.008
and P=0.02), but not for scSIVmac239 or scSIVmac155T3
(P.0.05 for all comparisons) (Figure 2A). Since SIVmac316 is
considerably more sensitive to neutralizing antibodies than
SIVmac239 or SIVmac155T3, better containment of scSIVmac316
may reflect the affinity maturation of envelope-specific neutraliz-
ing antibodies [43,44]. However, this was not supported by the
results of neutralization assays, since only one of the six animals in
this group had detectable neutralizing antibody titers to
SIVmac316 at the time of challenge. Therefore, other factors,
perhaps related to the lower infectivity of scSIVmac316, may have
contributed to the better containment of viremia for this strain.
In Group B, viral loads also peaked on day 4 after the first
inoculation, and with the exception of scSIVmac155T3 TMstop,
were resolved below the limit of detection within 3 to 6 weeks.
Consistent with the infectivity enhancement associated with
truncation of the gp41 cytoplasmic tail [35,36], peak viral loads
were 4.1-, 6.6- and 56-fold higher after the first dose for TMstop
versus TMopen scSIVmac239, scSIVmac155T3 and scSIVmac316
[32]. A delay in the clearance of viremia was also observed for
scSIVmac155T3 TMstop, particularly in animals Mm 350-03 and
Mm 465-02 (Figure 2B). The more prolonged period of viremia
for scSIVmac155T3 TMstop was significant based on area under
the curve comparisons with scSIVmac239 TMstop and scSIVmac316
TMstop [32], and may reflect preferential infection of a
CD4
+CXCR4
+ target cell population that is less susceptible to
the cytopathic effects of infection or more resistant to clearance by
virus-specific immune responses.
Trans-complementation of scSIV with VSV G resulted in a
dramatic infectivity enhancement, presumably by enabling CD42
and chemokine receptor-independent entry of scSIV into cell types
that are not normally permissive for SIV infection (Figure 2B).
Two days after boosting with VSV GI scSIV, peak viremia was
1.37610
5 RNA copy eq./ml. Relative to the first two doses of non-
trans-complemented scSIVmac239 TMopen in Group A, this
represents a 10-fold increase over the first peak (P=0.007) and a
415-fold increase over the second peak (P,0.001). The infectivity
enhancement for VSV GNJ scSIV was less dramatic, but was still
4-fold higher than the second non-transcomplemented dose of
scSIVmac239 TMopen in Group A (P=0.03).
Repeated immunization with single-cycle SIV did not
result in progressive increases in virus-specific T cell
frequencies
SIV-specific CD8
+ T cell responses to immunodominant epitopes
in Gag, Tat and Nef were monitored in Mamu-A*01 and -A*02
positive animals by directly staining peripheral blood with MHC
Class I tetramers. CD8
+ T cellresponses were detectableinGroup A
animals after the first two inoculations. However, subsequent rounds
of inoculation failed to boost CD8
+ T cell frequencies above the
threshold of detection (Figure 3A). Longitudinal analysis of virus-
specific T cellresponses by IFNc ELISPOT assays revealed a similar
pattern. Primary responses in Group A peaked within 2 to 3 weeks
after the first inoculation ranging from 165 to 308 (mean 261) spot-
forming cells (SFC) per million PBMC to Gag and from 198 to 635
(mean 327) SFC per million PBMC to Env (Figure 4A and 4B).
While recallresponses of comparable magnitude were observed after
the second inoculation, subsequent rounds of re-inoculation did not
result in additional increases in these virus-specific T cell frequencies
(Figure 4A and 4B). Thus, despite detectable plasma viremia
confirming the take of infection with each dose of scSIV, repeated
inoculation did not drive additional expansion of virus-specific T cell
responses.
Boosting with VSV G trans-complemented scSIV
increased virus-specific T cell frequencies and resulted in
broad T cell recognition of multiple viral antigens
Primary SIV-specific CD8
+ T cell responses in Group B were
similar to primary responses in Group A. However, these
responses increased dramatically after boosting with VSV G
trans-complemented scSIV. One week after the first boost, the
Figure 3. Boosting with VSV G trans-complemented single-cycle SIV significantly increases virus-specific CD8
+ T cell frequencies.
Responses are shown for Mm 182-99, Mm 89-00, and Mm 377-03 in Group A (A), and Mm 383-02, Mm 328-02, and Mm 295-00 in Group B (B). Whole
blood was stained with monoclonal antibodies to CD3 and CD8, and one of the following MHC class I tetramers; Mamu-A*01-Gag181–189, Mamu-A*01-
Tat28–35, or Mamu-A*02-Nef159–167. Samples were analyzed by flow cytometry, and the percentage of tetramer-positive cells was determined at each
time point after gating on the CD3
+CD8
+ lymphocyte population. Responses greater than 0.05% (dashed line) are considered positive.
doi:10.1371/journal.ppat.1000272.g003
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+ T cells in peripheral blood
increased 7- to 33-fold for Mamu-A*02 Nef159–167 (2.8% to 3.7%
CD8
+ T cells), 7- to 13-fold for Mamu-A*01 Gag181–189 (2.0% to
2.8% CD8
+ T cells) and 12- to 14-fold for Mamu-A*01-Tat28–35
(0.55% to 0.61% CD8
+ T cells) (Figure 3B). Additional recall
responses were observed after the second boost. However, with the
exception of one animal that made a Mamu-A*01 Gag181–189-
specific response that exceeded 13% of the circulating CD8
+ T cell
population (Figure 3B), these responses were generally lower
reflecting the lower take of infection for VSV GNJ scSIV than for
VSV GI scSIV (Figure 2B). Nevertheless, the majority of these
CD8
+ T cell responses remained above the threshold of detection
until the time of challenge twelve weeks later, indicating the
establishment of a memory CD8
+ T cell population.
Longitudinal analysis of IFNc T cell responses in Group B also
demonstrated significant expansion of virus-specific T cell responses
after boosting with VSV G trans-complemented scSIV. Peak
primary responses ranged from 122 to 506 (mean 273) SFC per
million PBMC to Gag and from 105 to 341 (mean 230) SFC per
million PBMC to Env (Figure 4C and 4D). One week after the first
boost, Gag-specific responses were 5.5-fold higher (mean 1496,
range 350 to 2595 SFC per million PBMC, P,0.001) and Env-
specific responses were 2.3-fold higher (mean 518, range 345 to 957
SFC per million PBMC, P=0.007) than peak primary responses.
Additional recall responses were observed after the second boost
(Figure 4C and 4D), and consistent with MHC class I tetramer
staining, the animal with the highest IFNc Tc e l lr e s p o n s et oG a g
was the same animal with the unusually high frequency of Mamu-
A*01 Gag181–189-specific CD8
+ T cells at week 25.
Whole-proteome IFNc ELISPOT assays also revealed broad T
cell recognition of each of the viral gene products expressed by
scSIV. The distribution of IFNc T cell responses to each viral
antigen for the animals in Group B is illustrated at week 13
(Figure 5A) and at week 25 (Figure 5B). Although there was
considerable animal-to-animal variation in the pattern of respons-
es reflecting the MHC diversity of these outbred animals, the
distribution of these responses was relatively stable after each
boost. Dominant T cell responses were directed against Gag in
three animals (Mm 328-02, Mm 350-03 and Mm 383-03), Env in
one animal (Mm 295-00) and Nef in another (Mm 465-02). Only
one animal (Mm 512-02) exhibited a notable shift from a diverse,
and relatively even distribution of responses to Gag, Nef, Vpr and
Vpx after the first boost, to a predominantly Gag-specific response
after the second boost (Figure 5). Hence, these results confirm the
activation of broad T cell responses capable of targeting each of
the 8 viral gene products expressed by scSIV.
Immunization with single-cycle SIV elicits virus-specific
CD4
+ T cell responses
Virus-specific CD4
+ T cell responses were also detectable after
boosting with VSV G trans-complemented scSIV. PBMC were
stimulated with a pool of overlapping Gag peptides in tubes coated
with co-stimulatory antibodies to CD28 and CD49d, and CD4
+ T
cells expressing TNFa and CD69 were detected by intracellular
cytokine staining according to methods described by Gauduin et al.
[45]. Gag-specific CD4
+ responses ranged from 0.10% to 0.27%
(mean 0.17% CD4
+ T cells) two weeks after the first boost
(Figure 6A). Increased Gag-specific CD4
+ T cell frequencies were
also observed in four of the six animals after the second boost
(Figure 6B). Virus-specific CD4
+ T cell responses are often weak or
undetectableinHIV-1infectedpeopleandSIV-infectedanimalsdue
to ongoing virus replication and turnover of CD4
+ lymphocytes,
[46,47]. Thus, the detection of CD4
+ T cell responses following
immunization with strains of SIV thatare limited toasingleround of
infection may reflect the uncoupling of CD4
+ T cell activation from
ongoing infection and destruction of these cells.
Figure 4. SIV Gag- and Env-specific IFNc T cell responses were boosted by VSV G trans-complemented single-cycle SIV. Gag- and Env-
specific IFNc T cell responses are shown for Group A (A,B) and Group B (C,D), respectively. PBMCs were stimulated with pools of overlapping peptides
representing the complete amino acid sequences of the SIV Gag and Env proteins, and IFNc-producing cells were enumerated after an overnight
incubation in ELISPOT assays. The average number of spot-forming cells (SFC) per million PBMC and the standard deviation (error bars) were
determined from duplicate wells set at 3610
5 or 1610
5 cells per well.
doi:10.1371/journal.ppat.1000272.g004
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PLoS Pathogens | www.plospathogens.org 6 January 2009 | Volume 5 | Issue 1 | e1000272Figure 5. Broad T cell recognition of each of the eight viral gene products expressed by single-cycle SIV. IFNc ELISPOT responses are
shown for Group B animals one week after each boost with VSV G trans-complemented scSIV, week 13 (A) and week 25 (B). Total responses to all 8
viral proteins are indicated in the center of each plot in SFC per million PBMC.
doi:10.1371/journal.ppat.1000272.g005
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+ T helper cell responses. SIV Gag-specific CD4
+ T cell responses
were measured by intracellular cytokine staining. (A) CD4
+ T cell responses are shown for each of the animals in Group B two weeks after the first
boost (week 14). The gated populations indicate CD4
+ T cells that have upregulated CD69 and TNFa after a 6-hour incubation in medium alone (R10)
or in medium containing a set of overlapping Gag peptides (Gag). (B) Changes in the frequency of Gag-specific CD4
+ T cells after each boost are
summarized as bar graphs. The percentages of activated CD69
+TNFa
+ cells reflect the difference between responses to the Gag peptide pool and
background responses in R10 medium. The arrows indicate booster inoculations on weeks 12 and 24.
doi:10.1371/journal.ppat.1000272.g006
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adapted, but not primary, isolates of SIV
Antibody responses to SIV were monitored longitudinally by
whole-virus ELISA. Plasma samples were tested at the time of
each inoculation and four weeks later for antibodies capable of
binding to plates coated with a lysate of purified virus particles.
SIV-specific antibody responses were detectable in all of the
animals by four weeks after the first inoculation (Figure 7). In
Group A, binding antibody responses waxed and waned with each
inoculation, but did not show an overall increase in titer
(Figure 7A). In Group B, significant increases in virus-specific
antibody titers were observed after the first boost at week 12
(P,0.001) followed by similar responses after the second boost at
week 24 (P=0.04) (Figure 7B).
At the time of challenge, neutralizing antibody titers were
measured against four different strains of SIV; a neutralization-
sensitive, lab-adapted strain of SIVmac251 (SIVmac251LA), and
three primary isolates, SIVmac316, SIVmac155T3 and SIVmac239,
matched in envelope with the scSIV strains included in the
inoculum. Plasma samples from three of the animals in Group A
and four of the animals in Group B neutralized SIVmac251LA
(,50% SEAP activity) at titers .80 (Figure 7C). Thus, both
immunization regimens elicited antibodies capable of binding to
the native, oligomeric conformation of envelope as it exists on
virions. However, little or no neutralization was observed for the
three primary isolates. While plasma samples from a couple of the
animals in each group had measurable neutralizing activity against
SIVmac316 and SIVmac155T3 at the lowest dilutions tested, none
of the animals made detectable neutralizing antibody responses
against SIVmac239 (Figure 7C). The inability to detect neutralizing
antibodies to SIVmac239 is not particularly surprising given the
inherent resistance of the 239 envelope glycoprotein to antibody-
mediated neutralization, even with plasma from animals persis-
tently infected with this virus [44,48].
Serotype-specific neutralizing antibodies to VSV G are
elicited by VSV G trans-complemented virus that can be
circumvented by changing VSV G serotypes
Plasma samples from Group B animals were also monitored for
neutralizing antibody titers to VSV G. Ten-fold dilutions of
plasma were tested for the ability to inhibit infection of CEM6174
cells by an env-deficient strain of SIV that was pseudotyped with
either the Indiana or the New Jersey serotype of VSV G. While
none of the animals had neutralizing antibody titers against either
serotype at the time of the first boost (week 12), some non-specific
inhibition of infectivity was observed at the lowest dilution of
plasma tested (Figure 8). This effect was greater for virus
pseudotyped with the New Jersey serotype than for virus
pseudotyped with the Indiana serotype of VSV G, an observation
that may account for the lower peak of viremia for VSV GNJ
scSIV than for VSV GI scSIV (Figure 2B). Nevertheless, four
weeks after boosting with VSV GI scSIV (week 16), plasma
samples from each of the six animals neutralized virus pseudo-
typed with the Indiana serotype of VSV G, but not the New Jersey
serotype of VSV G (Figure 8). Conversely, four weeks after
boosting with VSV GNJ scSIV (week 28), neutralizing antibody
titers to the New Jersey serotype of VSV G (50% neutralization
titer .500) were detectable in plasma from all six animals at a time
when neutralizing antibody titers to the Indiana serotype were
waning (Figure 8). These results are consistent with previous
studies demonstrating that the Indiana and the New Jersey
serotypes of VSV G do not elicit cross-reactive neutralizing
antibodies in animals infected with VSV glycoprotein exchange
vectors and validate our decision to change VSV G serotypes for
each boost [10,39].
Both immunization regimens afforded significant
containment of SIVmac239 replication and reduced
memory CD4
+ T cell loss after challenge
Twelve weeks after the last inoculation, each of the immunized
animals in Groups A and B, and four unvaccinated control
animals (Group C), were challenged intravenously with 10 animal
infectious doses of SIVmac239. With the exception of a single
animal in Group A (Mm 416-02), all of the animals became
infected (Figure 9A). This animal may in fact have been fully
protected, since the same stock of SIVmac239 has been used
extensively by our group, and by others, without a single failure to
establish infection in an unvaccinated control animal by the
intravenous route of challenge [12,28,49]. However, we could not
identify any differences in the immune responses of Mm 416-02
that might account for its resistance to infection. Furthermore,
single-cycle viral RNA load measurements after each dose of
scSIV were similar to the other animals in Group A suggesting that
there was no inherent genetic barrier to infection of this animal.
Therefore, to avoid inappropriately biasing our interpretation of
the outcome of challenge, this animal was not included in the
statistical analysis of post-challenge viral loads and CD4
+ T cell
counts.
Statistically significant reductions in viremia were observed in
both immunized groups relative to the control group in both acute
and chronic phases of infection. Area under the curve (AUC)
analysis revealed significant containment of total viral loads for
Group A (P=0.03) and for Group B (P=0.04) (Figure 9). Peak
viral loads measured within the first 2 weeks post-challenge were
12-fold lower for Group A (P=0.005) and 16-fold lower for Group
B (P=0.003), and set-point viral loads measured weeks 12–16
post-challenge were 52-fold lower for Group A (P=0.009) and 33-
fold lower for Group B (P=0.05). In contrast to previous vaccine
studies in which viral loads in immunized and control animals
were indistinguishable by 40 weeks post-challenge [12,13], these
differences in chronic phase viral loads were stable for more than
one year after infection (Figure 9). Indeed, comparisons of the
geometric means of viral loads for each group over weeks 12–56
post-challenge using a linear mixed model analysis indicated that
these chronic phase differences were statistically significant for
both Group A (P=0.015) and B (P=0.014). Thus, both
immunization regimens afforded significant containment of virus
replication after an intravenous challenge with SIVmac239.
Differences in the loss of memory CD4
+ T cells were also
observed for immunized versus control animals. There were no
differences in the decline of total or naive CD4
+ T cells (P=0.7
and P=0.2 respectively) (Figure 10A–10D). However, AUC
analysis indicated significantly better preservation of the memory
CD4
+ T cell subsets in each of the immunized groups (Figure 10E–
10J). The central, effector and CCR5
+ memory CD4
+ T cell
populations were all significantly higher in Group A than in Group
C (P=0.03, P=0.03 and P=0.01 respectively). Likewise, the
central and CCR5
+ memory CD4
+ T cell populations were
significantly higher in Group B than in Group C (P=0.05 and
P=0.03). Only the comparison of effector memory CD4
+ T cell
counts in Group B versus Group C fell short of statistical
significance (P=0.06). These results are consistent with the
preferential infection and turnover of memory CD4
+ T cells by
SIVmac239 [33], and provide additional evidence of partial
protection by each immunization regimen.
To identify potential correlates of protection, associations
between the immune responses elicited by scSIV and post-
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PLoS Pathogens | www.plospathogens.org 10 January 2009 | Volume 5 | Issue 1 | e1000272Figure 8. Neutralizing antibody responses to VSV G are serotype-specific. Plasma samples from Group B animals were tested for the ability
to inhibit infection of CEM6174 cells by a VSV G-pseudotyped, env-deficient strain of SIV that expresses EGFP from the nef-locus. Neutralization
curves for SIVDenvEGFP pseudotyped with the Indiana and the New Jersey serotypes of VSV G are shown in the top and bottom rows, respectively.
The percentage of infected, EGFP
+ cells for virus incubated with plasma relative to virus incubated without plasma was determined by flow cytometry
after 4 days of infection. Pooled plasma from three naive donor macaques was used as a negative control (Neg. Pool). The dotted line indicates 50%
neutralization of virus infectivity.
doi:10.1371/journal.ppat.1000272.g008
Figure 9. Both immunization regimens afford significant containment of SIVmac239 replication after challenge. Each of the scSIV-
immunized animals in Groups A and B and four unimmunized control animals (Group C) were challenged intravenously with 10 animal infectious
doses (1.5 pg p27) of SIVmac239. Viral loads for individual animals (A) and the geometric means for each group (B) are shown. Viral RNA loads were
determined using a quantitative reverse-transcription-PCR assay with a threshold of detection of 15 copy eq./ml (dotted line). Mm 416-02 did not
become infected and was not included in the calculation of the geometric mean for Group A. At the time that this manuscript was prepared, 7 of the
16 animals in this study had been euthanized with symptoms of AIDS. These animals included Mm 370-03 (week 27), Mm 465-02 (week 30), Mm 350-
03 (week 49), Mm 349-03 (week 51), Mm 377-03 (week 60), Mm 295-00 (week 65), and Mm 364-03 (week 68). The clinical conditions of these animals
at the time of euthanasia are described in the Materials and Methods section.
doi:10.1371/journal.ppat.1000272.g009
Figure 7. Both immunization regimens elicited antibody responses capable of neutralizing lab-adapted, but not primary isolates of
SIV. Binding antibody responses were measured for Group A (A) and Group B (B) animals at a 1/20 dilution of plasma on ELISA plates coated with
whole-virus lysate. The mean and standard deviation (error bars) of the antibody responses in each group are plotted in gray. Arrows indicate the
time points of each inoculation, and the dashed line indicates the mean level of non-specific binding for pre-immune plasma at the time of the first
inoculation. (C) SIV-specific neutralizing antibody titers at the time of challenge. Serial two-fold dilutions of plasma were tested for the abilityt o
inhibit infection of target cells harboring a Tat-inducible SEAP reporter gene by lab-adapted SIVmac251 (SIVmac251LA), SIVmac316, SIVmac155T3, and
SIVmac239. The dashed line in each plot indicates 50% neutralization of virus infectivity.
doi:10.1371/journal.ppat.1000272.g007
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analysis. IFNc T cell responses to Gag and Env, at peak and at the
time of challenge, were compared to peak and set-point viral loads
after challenge. Neutralizing antibody titers to SIVmac251LA and
binding antibody responses to whole-virus at the time of challenge
were also compared to peak and set-point viral loads after
challenge. Additional associations were tested between peak single-
cycle viremia for each strain of scSIV and peak viral loads during
the acute phase of infection. None of these comparisons revealed
significant correlations between parameters measured during the
immunization phase of the study and viral loads post-challenge.
Therefore, similar to previous studies with live, attenuated SIV
[50], no correlations were observed between immune responses
elicited by scSIV and the outcome of challenge.
Discussion
More than 25 years after the emergence of the global HIV-1
pandemic, the development of a safe and effective AIDS vaccine
remains an elusive scientific challenge. Although passive transfer
studies have demonstrated that high concentrations of broadly
neutralizing antibodies in plasma can provide sterilizing immunity
to SHIV infection of macaques [51–54], it is presently unclear how
to elicit such antibody responses by vaccination. Thus, efforts of
the vaccine community have focused on T cell-based vaccines
designed to reduce viral loads in immunized individuals who later
become infected with the goal of reducing the incidence of HIV-1
transmission to new hosts. This strategy is supported by
epidemiological data showing that the risk of heterosexual HIV-
1 transmission is directly related to viral loads of the donor, and
that individuals with plasma viral loads less than 1500 RNA
copies/ml rarely transmit their infections to their partners [55].
Several recombinant vaccine candidates have been developed
based on this premise that are designed to stimulate potent cellular
immune responses [8–11,16,17]. However, the extent of protec-
tion achieved by these vaccines has so far been disappointing [12–
19]. Live, attenuated strains of SIV afford more reliable protection
in animals, often achieving sterilizing immunity against closely
related challenge viruses [1–3]. However, due to the potential to
regain a pathogenic phenotype during persistent replication in vivo,
there are justifiable safety concerns with the use of live, attenuated
HIV-1 as a vaccine approach in humans [4–6].
To uncouple the activation of virus-specific immune responses
from persistent virus replication, we devised a genetic system for
producing strains of SIV that are limited to a single round of
infection [25,28]. Single-cycle SIV retains many of the potentially
advantageous properties of live, attenuated SIV, including the
expression of 8 of the 9 viral antigens, the absence of any vector-
derived gene products, and the expression of the native, oligomeric
conformation of envelope on the surface of infected cells and
virions. However, unlike attenuated vaccine strains, scSIV is not
replication-competent and cannot revert to a pathogenic pheno-
type as a result of the accumulation of compensatory genetic
changes during persistent replication in vivo.
Contrary to our initial hypothesis of ‘‘immunization to
extinction,’’ repeated immunization with scSIV did not lead to
the progressive maturation of virus-specific immune responses or
successive decreases in single-cycle viremia. While SIV-specific T
cell responses were detectable by MHC class I tetramer staining
and IFNc ELISPOT assays after the first and second doses,
subsequent rounds of inoculation did not result in additional recall
responses. These results are similar to previous observations [28],
but are nevertheless puzzling given that viral RNA load
measurements in plasma indicate a consistent take of infection
after each inoculation. One possibility is that the T cell responses
elicited by the first two doses were sufficient to resolve later rounds
of scSIV infection with faster kinetics, thereby curtailing additional
T cell activation and proliferation. Alternatively, repeated
immunization may have had a tolerizing effect, perhaps by
eliciting regulatory CD4
+ T cell responses or inducing a state of
clonal anergy. While the immunological basis for this phenome-
non is presently unclear, the mechanism(s) responsible for
permitting a certain level of scSIV infection without a detectable
expansion of virus-specific T cell responses may ultimately
account, at least in part, for the inability of natural immunity to
resolve wild-type HIV-1 or SIV infection.
In contrast, boosting with VSV G trans-complemented scSIV
dramatically increased virus-specific T cell frequencies. One week
after the first boost, SIV-specific CD8
+ T cell frequencies to
immunodominant epitopes in Gag, Tat and Nef ranged from
0.55% to 3.7% of the CD8
+ T cell population in peripheral blood.
These responses were more than 10-fold higher than peak
responses elicited after the initial priming dose, and are
comparable to peak CD8
+ T cell responses after boosting with
recombinant poxviral or adenoviral vectors [8,11–13]. These
responses are also similar to Gag181–189-specific CD8
+ T cell
frequencies following the acute phase of SIVmac239 infection,
which typically range from 0.5% to 10% of circulating CD8
+ T
cells [56]. Since the particle doses of VSV G trans-complemented
and non-trans-complemented scSIV were similar for each
inoculation (ranged from 10 to 15 mg p27), the greater magnitude
of T cell responses after boosting with VSV G scSIV presumably
reflects increased virus infectivity, and hence greater numbers of
scSIV-infected antigen presenting cells after immunization.
However, we cannot exclude the possibility that VSV G may
also have facilitated scSIV entry into dendritic cells, or other
professional antigen presenting cells, that potently activate T cell
responses.
Gag-specific CD4
+ T cell responses were also detectable by
intracellular cytokine staining after boosting with VSV G trans-
complemented scSIV. Although most HIV-1 infected patients and
SIV infected animals make virus-specific CD4
+ T cell responses,
these responses are usually kept in check by ongoing virus infection
[46,57–59]. Higher frequencies of virus-specific CD4
+ T cells have
been observed in certain individuals who are better able to control
HIV-1 infection and in animals persistently infected with live,
attenuated strains of SIV [57,59]. These observations suggest that
virus-specific CD4
+ T cells may be important for controlling HIV-
1 and SIV infection, or alternatively, that better containment of
virus replication may reduce CD4
+ T cell turnover. By uncoupling
CD4
+ T cell activation from ongoing infection and destruction of
these cells, scSIV may facilitate the development of virus-specific
Figure 10. Memory CD4
+ T cell subsets are better preserved in scSIV-immunized animals after challenge. Post-challenge CD4
+ T cell
counts in peripheral blood are shown for total (A,B), naive (C,D), central memory (E,F), effector memory (G,H), and CCR5
+ memory (I,J) subsets. CD4
+ T
cell counts for individual animals are shown on the left (A,C,E,G,I), and the arithmetic means for each group are shown on the right (B,D,F,H,J). Whole
blood was stained with monoclonal antibodies to CD3, CD4, CD28, CD95, and CCR5 to differentiate naive (CD28
+CD95
2), central memory
(CD28
+CD95
+), effector memory (CD28
2CD95
+), and CCR5
+ memory (CD95
+) CD4
+ T cells. The percentages for each population were determined by
flow cytometry, and total cell counts were determined by complete blood count analysis at each time point.
doi:10.1371/journal.ppat.1000272.g010
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+ T cell responses. Since CD4
+ helper T cells play a central
role in the maintenance of effective antibody and CTL responses
to viral infections [60–65], these responses are likely to be an
important component of an effective AIDS vaccine.
Both immunization regimens elicited similar neutralizing
antibody titers to a lab-adapted strain of SIVmac251, verifying
the induction of antibodies capable of binding to the native,
oligomeric conformation of envelope as it exists on virions.
However, only a couple of the animals in each group made low-
titer neutralizing antibody responses to SIVmac316 and SIV-
mac155T3, and none of the animals had detectable neutralizing
antibodies to SIVmac239. These observations reflect the greater
resistance of primary isolates to neutralizing antibodies, particu-
larly for SIVmac239 [44], and highlight the difficulty of eliciting
even strain-specific neutralizing antibodies to viruses that express
neutralization-resistant envelope glycoproteins typical of naturally
transmitted HIV-1 field isolates. These results also suggest that
envelope-specific antibodies were probably not a significant factor
in protection against SIVmac239 at the time of challenge, although
they do not preclude a role for anamnestic antibody responses in
the control of virus replication after infection.
Following an intravenous challenge with SIVmac239, statistically
significant reductions in viral loads and higher memory CD4
+ T
cell counts were observed for both groups of scSIV immunized
animals. Relative to the unvaccinated control group, peak and set-
point viral loads were 12- and 52-fold lower for the animals
immunized by repeated inoculation (P=0.005 and P=0.009), and
16- and 33-fold lower for the animals immunized by the prime and
boost regimen (P=0.003 and P=0.05). Furthermore, both groups
of immunized animals maintained significantly better control of
virus replication during the chronic phase of infection for more
than one year after challenge. Based on prior associations of viral
loads with HIV-1 transmission rates in humans, these reductions
in set-point viral loads are in a range that might be expected to
have a significant impact on heterosexual transmission [22,55].
While encouraging, the extent of protection achieved by
immunization with scSIV in these studies was not as good as
typically afforded by infection with live, attenuated SIV [1–3].
This difference may have important implications to our under-
standing of the mechanisms of protection by live, attenuated
vaccine strains. In contrast to scSIV immunization, which
activates virus-specific immune responses that appear to decline
into memory after the clearance of productively infected cells,
attenuated strains of SIV continuously stimulate antibody and T
cell responses as a consequence of persistent virus replication.
Persistent antigenic simulation may have significant qualitative
and quantitative effects on virus-specific immune responses.
Animals infected with SIVmac239Dnef develop unusually high
virus-specific CD4
+ T cell frequencies with predominantly effector
memory phenotypes [59], presumably reflecting ongoing antigenic
stimulation. These responses, which can represent up to 4–10% of
circulating CD4
+ lymphocytes, are considerably higher than the
CD4
+ T cell responses elicited by scSIV immunization in this
study, or indeed by wild-type SIV infection in previous
comparisons [59]. By providing a constant source of infected
antigen presenting cells, attenuated vaccine strains may also
maintain CD8
+ T cell responses in an activated state that allows
for more rapid recognition and clearance of productively infected
cells. In support of this, Rollman et al. observed that Gag-specific
CD8
+ T cells from macaques infected with an attenuated strain of
SIV degranulated within 30 minutes after stimulation versus more
than 3 hours for Gag-specific CD8
+ T cells elicited by vaccination
with recombinant poxviral vectors [66]. In the case of antibody
responses, ongoing replication by live, attenuated viruses may
drive the affinity maturation of envelope-specific neutralizing
antibodies. Although passive transfer of serum from animals
infected with attenuated viruses has not conferred protection [67],
the time dependence of protective immunity [3,68], and associated
changes in the avidity and conformational dependence of
envelope-specific antibodies [69], suggest that affinity maturation
of neutralizing antibody responses may contribute to protective
immunity. Thus, persistent virus replication and immune
activation may be essential to achieve the degree of protection
afforded by live, attenuated SIV.
SIVmac239 is a notoriously difficult strain to protect against by
vaccination, particularly by the intravenous route of challenge.
Prime and boost vaccine regimens using recombinant DNA and
either poxviral or adenoviral vectors that were able to effectively
contain virus replication after challenge with SHIV89.6P afforded
little or no protection against SIVmac239 [8,11–13]. In some cases,
these vaccine approaches succeeded in reducing acute phase viral
loads by approximately one log, but did not provide long-term
control of SIVmac239 replication during the chronic phase of
infection [12,13]. Similar reductions in acute phase viral loads
without long-term control of virus replication have also been
observed when protection was assessed by challenging with
uncloned, pathogenic SIVmac251 [16,17]. In one study, better
containment of SIVmac239 replication during the chronic phase of
infection was achieved by vaccination of animals with a
multivalent DNA-prime, rAd5-boost approach [14]. However,
all of the animals in this study were Mamu-A*01 positive, and since
Mamu-A*01 is associated with better control of SIV infection [70],
MHC class I immunogenetics may also have contributed to the
better outcome of challenge in these animals [14]. Other vaccine
studies that have reported more effective control of SIVmac239
replication have typically used rhesus macaques of Chinese or
Burmese origin [71,72]. Since genetic evidence suggests that
Chinese and Indian origin rhesus macaques represent distinct
populations that separated approximately 162,000 years ago [73],
and Chinese origin rhesus macaques have significantly lower viral
loads and slower courses of disease progression after SIVmac239 or
SIVmac251 infection than Indian origin rhesus macaques [74,75],
genetic differences between these two populations may account for
the better vaccine protection observed in Chinese origin rhesus
macaques. Thus, with the notable exception of live, attenuated
SIV, the control of SIVmac239 replication achieved in this study by
immunization with scSIV was at least as good, if not better than,
other vaccine approaches that have been evaluated in this
challenge model. A better understanding of the differences in
immune responses elicited by immunization of macaques with
single-cycle SIV versus live, attenuated SIV may provide
important insights into the design of more effective vaccines for
protection against HIV-1.
Materials and Methods
Animals
All of the animals used for these studies were Indian origin
rhesus macaques (Macaca mulatta). These animals were housed in a
biosafety level 3 containment facility at the New England Primate
Research Center (NEPRC) and were maintained in accordance
with standards of the Association for Assessment and Accreditation
of Laboratory Animal Care and the Harvard Medical School
Animal Care and Use Committee. Animal experiments were
approved by the Harvard Medical Area Standing Committee on
Animals and conducted according to the principles described in
the Guide for the Care and Use of Laboratory Animals [76]. All the
animals selected for this study were negative for simian retrovirus
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herpesvirus B.
All of the animals in this study were typed for the rhesus
macaque MHC class I alleles Mamu-A*01, -A*02, -A*08, -A*11, -
B*01, -B*03, -B*04, -B*08, -B*17 and -B*29. The MHC class I
alleles present in each animal are summarized in Table 1. Since
Mamu-A*01 is associated with better control of SIV infection [70],
the number of Mamu-A*01 positive animals assigned to each group
was balanced to avoid a genetic bias in the outcome of challenge
due to overrepresentation of this allele. Animals that were positive
for both Mamu-A*01 and -B*17,o rMamu-A*01 and -B*08, and
thus more likely to spontaneously control SIV infection indepen-
dent of vaccination [70,77–79], were excluded. MHC class I
typing was performed by allele-specific PCR from genomic DNA
using the primers and reaction conditions described by Kaizu et al.
[80]. These assays were performed in Dr. David Watkins’
laboratory at the Wisconsin National Primate Research Center
(WNPRC, Madison, WI).
At the time that this manuscript was prepared, seven of the
sixteen animals in this study had been euthanized with symptoms
of AIDS. The week each animal died post-challenge, the
experimental group the animal was assigned to, and the clinical
conditions of the animal at the time of euthanasia are as follows.
Mm 370-03 (Group C) was euthanized at week 27 post-challenge
due to weight loss, persistent epistaxis and increased respiratory
effort. Mm 465-02 (Group B) was euthanized at week 30 post-
challenge with enlarged lymph nodes due to a progressive history
of weight loss and diarrhea. Mm 350-03 (Group B) was
euthanized at 49 weeks post-challenge due to periorbital edema,
an enlarged spleen, an enlarged liver and agitated behavior. Mm
349-03 (Group C) was euthanized at 51 weeks post-challenge
due to diarrhea and moderate weight loss with enlarged spleen
and lymph nodes. Mm 377-03 (Group A) was euthanized at week
61 post-challenge with generalized lymphadenopathy and an
enlarged spleen. Mm 295-00 (Group B) was euthanized at week
65 post-challenge with an enlarged spleen, lymphadenopathy
and neurological symptoms. Mm 364-03 (Group A) was
euthanized at week 68 post-challenge due to weight loss,
diarrhea and lethargy.
Sequence-tagged envelope variants of single-cycle SIV
Six different envelope variants of scSIV were constructed as
previously described [32]. These included strains expressing full-
length (TMopen) and truncated (TMstop) forms of the 239, 316 and
155T3 envelope glycoproteins. The TMstop strains contained a
glutamic acid to stop-codon change at position 767 (E767*) that
truncates the cytoplasmic domain of gp41 and results in increased
envelope incorporation into virions and increased virus infectivity
[35]. Unique 71–74 bp sequence tags selected from the Arabidopsis
thaliana genome were introduced into the pol locus to allow
independent quantification of viral RNA loads by real time RT-
PCR analysis for each strain after mixed inoculation [32]. To
facilitate the stimulation of virus-specific CTL responses, 26
residues from the C-terminus of the Nef protein that are required
for MHC class I down regulation were eliminated by a glycine to
stop-codon change at position 238 of Nef (G238*) followed by two
single-nucleotide deletions (D9791 and D9797) [28,37].
Preparation of concentrated stocks of scSIV
Single-cycle SIV was produced by co-transfection of 293T cells
with the Gag-Pol expression construct pGPfusion and a full-length
proviral DNA construct for each scSIV strain as previously
described [25,28,32]. 293T cells were seeded at 5610
6 cell per
100-mm dish in cell culture medium (Dulbecco’s modified Eagle’s
medium [DMEM] supplemented with 10% fetal bovine serum
[FBS], L-glutamine, penicillin and streptomycin) and transfected
the following day with 5 mg of each plasmid using TransFectin
TM
Lipid Reagents (Bio-Rad, Hercules, CA). To produce VSV G
trans-complemented scSIV, 5 mg of an expression construct for the
Indiana or the New Jersey serotype of VSV G was included in the
transfection mix. The cDNA clone for the New Jersey serotype of
VSV G was kindly provided by Dr. John Rose (Yale University
School of Medicine, New Haven, CT). Twenty-four hours after
Table 1. MHC class I alleles present in the rhesus macaques selected for this study.
Group Animal A*01 A*02 A*08 A*11 B*01 B*03 B*04 B*08 B*17 B*29
A Mm 182-99 + 2 2 2 222222
Mm 89-00 + 2 2 2 222222
Mm 377-03 2 + 2 2 222222
Mm 457-02 22222 2 2 2 ++
Mm 416-02 2 2 2 2 222222
Mm 364-03 2222+ 22222
B Mm 328-02 + 2 2 2 222222
Mm 383-03 ++22+ 22222
Mm 295-00 2 ++2 222222
Mm 465-02 2222+ 22222
Mm 512-02 2222+ 22222
Mm 350-03 2222+ 22222
C Mm 513-02 + 2 2 2 222222
Mm 349-03 2 + 22+ 22222
Mm 370-03 2222+ 22222
Mm 382-03 2222+ 22222
MHC class I typing was performed by allele-specific PCR as described in Kaizu et al. [80].
doi:10.1371/journal.ppat.1000272.t001
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and the cell culture medium was replaced with DMEM
supplemented with 10% rhesus serum (Equitech-Bio, Kerrville,
TX). Twenty-four hours later, the cell culture supernatant was
collected and concentrated by repeated low speed centrifugation in
YM-50 ultrafiltration units (Millipore, Bedford, MA). One-
milliliter aliquots of scSIV were cryopreserved at 280uC and the
concentration of virus was determined by SIV p27 antigen capture
ELISA (Advanced BioScience Laboratories, Kensington, MD).
Single-cycle infectivity assays
One million CEM6174 cells were incubated with 100 ng p27
equivalents of scSIV in 100 ml volume for 2 hours at 37uC. Cultures
were then expanded to a volume of 2 ml in R10 medium (RPMI
supplemented with 10% FBS, L-glutamine, penicillin and strepto-
mycin) and incubated in 24-well plates at 37uC for 4 days. Cells were
treated with Caltag Fix and Perm reagents (Caltag Laboratories,
Burlingame, CA) and stained with the FITC-conjugated SIV Gag-
specific monoclonal antibody 2F12 (provided by the DAIDS/
NIAID Reagents Resource Support Program for AIDS Vaccine
Development, under contract to Quality Biological, Inc. and Bio-
Molecular Technology, Inc.; Principal Investigator, Ronald Brown;
Project Officer, Jon Warren). After staining, cells were fixed in 2%
paraformaldehyde PBS and analyzed by flow cytometry to
determine the frequency of SIV Gag-positive infected cells.
Immunization of macaques with scSIV
Six macaques (Group A) were inoculated intravenously with 6
identical doses of scSIV at 8-week intervals. Each dose contained a
mixture of scSIVmac239 TMopen, scSIVmac316 TMopen and
scSIVmac155T3 TMopen (5 mg p27 eq. of each strain). Six
additional animals (Group B) were inoculated intravenously with
an initial priming dose that included scSIVmac239 TMstop,
scSIVmac316 TMstop and scSIVmac155T3 TMstop (5 mg p27 eq.
of each strain). These animals were then boosted on weeks 12 and
24 with VSV G trans-complemented scSIVmac239 TMopen. The
first boost contained 10 mg p27 eq. of scSIV trans-complemented
with the Indiana serotype of VSV G (VSV GI) and the second
boost contained 13 mg p27 eq. of scSIV trans-complemented with
New Jersey serotype of VSV G (VSV GNJ). For each inoculation,
2–3 ml of concentrated scSIV was injected through a 22-gauge
catheter placed aseptically in the saphenous vein of ketamine-HCI
anesthetized animals (15 mg/kg intramuscularly).
MHC class I tetramer staining
Virus specific CD8
+ T cell responses were measured in the
peripheral blood of Mamu-A*01 and -A*02 positive rhesus
macaques. Whole blood (200 ml) was incubated for 30 min at
37uC with one of the following APC-conjugated tetramers
provided by Dr. David Watkins’ laboratory at the Wisconsin
National Primate Research Center (University of Wisconsin,
Madison, WI); Mamu-A*01-Gag181–189, Mamu-A*01-Tat28–35
and Mamu-A*02-Nef159–167. The samples were then stained with
anti-CD3-FITC (clone SP34, BD Pharmingen) and anti-CD8-
PerCP (clone SK1, BD Biosciences) monoclonal antibodies for an
additional 30 min at room temperature. After staining, the
samples were treated with FACS Lysing solution (BD Biosciences)
to eliminate red blood cells, washed and fixed in 2% paraformal-
dehyde PBS. Data was collected using a FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA) and the frequency of
CD8
+ T cells staining with each tetramer was determined by
analysis using the FlowJo software package (Tree Star, San Carlos,
CA).
IFN-c ELISPOT assays
Virus-specific T cell responses were measured using enzyme-
linked immunospot (ELISPOT) assay. PBMCs were plated at
3610
5,1 610
5 and 3610
4 cells per well in multiscreen 96-well
plates (Millipore) coated with an IFNc capture antibody (Mabtech,
Mariemont, OH). PBMCs were stimulated in duplicate wells with
peptide pools (15-mers overlapping by 11 amino acids, 2.5 mg/ml
for each individual peptide) representing the amino acid sequences
of the SIV Gag, Env, Nef, Tat, Rev, Vpr, Vpx and Vif antigens.
Plates were incubated overnight at 37uC and developed using an
enzyme-linked, colorimetric assay for bound IFNc (Mabtech).
Spots representing IFNc-producing T cells were enumerated using
an automated ELISPOT plate reader (Zellnet Consulting, New
York, NY). The frequency of spot-forming cells (SFC) per million
PBMC was calculated by subtracting the number of background
spots in medium control wells from the number of spots in peptide-
stimulated wells and adjusting for the input cell number.
Intracellular cytokine staining
SIV-specific CD4
+ T helper cell responses were detected by
intracellular cytokine staining (ICS) as previously described [45].
Polystyrene flow tubes (12675 mm) were coated overnight at a 5u
angle at 4uCw i t h2 . 5mg/ml goat anti-mouse IgG (H+L) (KPL,
Gaithersburg, MD). The next day, the tubes were incubated with
10 mg/ml mouse anti-human-CD28 (clone CD28.2, BD Pharmin-
gen) and mouse anti-human-CD49d (clone 9F10, BD Pharmingen)
antibodies at 37uC for 1 hour. Fresh PBMC (1.5–2610
6)w e r e
stimulated at 37uC with the Gag peptide pool (2 mg/ml), SEB
(100 ng/ml) or complete R10 medium in the presence of cross-
linked co-stimulatory CD28 and CD49d antibodies. Brefeldin A
(GolgiPlug, BD Pharmingen) was added after one hour and the
incubation was continued for another five hours. After 6 hours of
antigen stimulation, PBMC were surface-stained with anti-CD3-
FITC (clone SP34, BD Pharmingen) and anti-CD4-PerCP mono-
clonal antibodies (clone L200, BD Pharmingen) at 4uCf o r3 0m i n .
The cells were then treated with Fix & Perm reagents (Caltag
Laboratories) and stained with anti-CD69-PE (clone FD50, BD
Biosciences) and anti-TNFa-APC (clone Mab11, BD Pharmingen)
at room temperature for 50 min. Cells were then fixed in fresh 1%
paraformaldehyde PBS. Data were collected using a FACSCalibur
flow cytometer collecting .200,000 lymphocyte events per sample
and analyzed using the FlowJo software package.
SIV-specific binding antibodies
SIV-specific binding antibodies were detected by whole-virus
ELISA. Nunc-immunoplates (Fisher, Pittsburgh, PA) were coated
overnight at room temperature with 0.1 mg p27 eq/ml whole-virus
lysate prepared from aldrithiol-2 inactivated SIV CP-MAC (AIDS
Vaccine Program, NCI-Frederick, Frederick, MD) [81]. Plates
were blocked with a 1:30 dilution of Kirkegaard and Perry BSA
dilute/blocking solution concentrate (KPL, Gaithersburg, MD)
and washed once with water. Duplicate 1:20 dilutions of plasma
were incubated in pre-treated wells for 1 hour. After 3 washes,
100 ml alkaline phosphatase conjugated Goat anti-human IgG (Fc)
(KPL) at a dilution of 1:100 was added to each well for 1 hour.
The plates were then washed three times and 200 mlo f
phosphatase substrate solution (KPL) was added to each well.
After 30 min, the reaction was stopped by the addition of 50 ml3 N
sodium hydroxide and the absorbance was read at 405 nm.
Neutralizing antibody responses to SIV
Neutralizing antibody titers were measured by the ability of
plasma to block infection of target cells harboring a Tat-inducible
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two-fold dilutions of plasma were incubated with lab-adapted
SIVmac251 (0.25 ng p27 eq), SIVmac316 (5.0 ng p27 eq.),
SIVmac155T3 (1.0 ng p27 eq.) or SIVmac239 (1.0 ng p27 eq.) in
96-well plates at 100 ml per well. After a one-hour incubaf-
tion, 30,000 C8166 SIV-SEAP (SIVmac251LA, SIVmac239 and
SIVmac155T3) or CEM6174-SEAP (SIVmac316) cells were added
in an additional 100 ml R10 medium. SEAP activity was
determined in culture supernatant collected on day 3 for
SIVmac251LA, SIVmac239 and SIVmac155T3 and on day 5 for
SIVmac316 using the Phospha-Light SEAP detection kit (Applied
Biosystems, Foster City, CA). Mock-infected cells and SIV-infected
cells incubated in the absence of plasma were used to determine
background and maximal SEAP production respectively. After
subtracting the background activity, percent neutralization was
calculated by dividing the mean SEAP counts for replicate wells at
each plasma dilution by the maximal SEAP counts in the absence
of plasma.
VSV G-specific neutralizing antibody responses
VSV G-specific neutralizing antibody responses were measured
by testing 10-fold dilutions of plasma for the ability to inhibit
infection of CEM6174 cells by a VSV G-pseudotyped, env-
deficient strain of SIV that expresses EGFP from the nef-locus
(SIVmac239DEnvEGFP) [82]. The expression of the SIV envelope
glycoprotein by SIVmac239DEnvEGFP was disrupted by intro-
ducing a combination of nucleotide substitutions that changed the
second and third codons of env to stop-codons and introduced a
single nucleotide frameshift deletion (ATGGGATGTCTT -.
ATGTGAT-AATT). VSV G-pseudotyped stocks of SIVmac239-
DEnvEGFP were produced by co-transfection of 293T cells with
SIVmac239DEnvEGFP proviral DNA and expression constructs
for either the Indiana or the New Jersey serotypes of VSV G. Ten-
fold dilutions of plasma (1/20,1/200 and 1/2000) were incubated
with 20 ng p27 eq. of VSV G-pseudotyped SIVmac239DEnvEGFP
for one hour at 37uC in 100 ml R10 medium. CEM6174 cells
(2.5610
5) were added, and the incubation was continued for an
additional 2 hours in a total volume of 200 ml R10 medium. The
cultures were expanded to one ml and transferred to 48-well
plates. Four days later, the cells were harvested, fixed in 2%
paraformaldehyde PBS and the frequency of infected EGFP
+ cells
was determined by flow cytometry. Percent infectivity was
calculated by dividing the mean percentage of EGFP
+ cells at
each dilution of plasma by the mean percentage of EGFP
+ cells in
the absence of plasma and multiplying by 100.
Intravenous challenge with SIVmac239
The immunized and control animals were challenged
intravenously with SIVmac239. A vial of SIVmac239 challenge
stock prepared in activated rhesus macaque PBMC (provided by
Dr. Ronald Desrosiers, NEPRC) was thawed and diluted to 10
animal infectious doses (1.5 pg p27 eq.) per ml in serum-free
RPMI 30 minutes prior to challenge. Under ketamine-HCl
anesthesia (15 mg/kg, i.m.), each animal received one ml of the
virus dilution through a 22 g catheter placed aseptically in the
saphenous vein.
Plasma viral RNA load measurements
Virus was recovered from 0.5 to 1.5 ml plasma collected in
sodium citrate anticoagulant by centrifugation and viral RNA was
extracted and reverse-transcribed into cDNA as previously
described [83]. Single-cycle viral loads were measured using a
quantitative, multiplex, real-time RT-PCR assay specific for
unique sequence tags (ggr, cao and gsa) carried by each strain of
scSIV. The primer/probe sets and reaction conditions for this
multiplex assay are described in DeGottardi et al. [32]. Post-
challenge viral RNA loads for SIVmac239 were measured using a
standard quantitative, real-time, RT-PCR assay based on
amplification of sequences in gag [83]. The nominal threshold of
detection for this assay is 25 RNA copy eq. per ml and the
interassay coefficient of variation is ,25%.
CD4
+ T cell subsets post-challenge
The loss of total, naive and memory CD4
+ T cell subsets was
monitored after challenge. Whole blood was stained with the
monoclonal antibodies CD3-FITC (clone SP34, BD Pharmingen),
CD4-PerCP (clone L200, BD Pharmingen), CD95-APC (clone
DX2, BD Pharmingen), and CD28-PE (clone CD28.2, BD
Pharmingen) or CCR5-PE (clone 3A9, BD Pharmingen). Eryth-
rocytes were eliminated by treatment with FACS Lysing solution
(BD Biosciences) and the cells were fixed in 2% paraformaldehyde
PBS solution. At each time point, the total number of lymphocytes
was determined by complete blood count (CBC) analysis. Cell
counts per ml of blood for each CD4
+ T cell subset were calculated
by multiplying the number of lymphocytes at each time point by
the percentage of total, naive (CD28
+CD95
2), central memory
(CD28
+CD95
+), effector memory (CD28
2CD95
+) and CCR5
+
memory (CCR5
+CD95
+) CD4
+ T cells.
Statistical methods
Paired t-tests were used to assess differences in viral RNA load
measurements and virus-specific T cell responses over time in the
same animals. Independent sample t-tests were used to assess
differences in these variables across groups at specific time points
and to test differences between groups for area under the curve
comparisons. Associations between immune responses elicited by
scSIV and log-transformed, post-challenge viral RNA loads in
plasma at peak and at set-point (week 12) were examined by linear
regression analysis. Linear mixed models were also applied to
analyze differences between groups in mean viral RNA load
measurements during the chronic phase of infection (weeks 12–56
post-challenge) [84]. This method makes efficient use of all data
points available and accounts for correlations between repeated
measurements on the same animals. In this analysis, each animal
was assumed to be completely randomized to one of three
experimental groups, and thus assumed to be independent from
each other. Animal-specific intercepts and group-specific slopes
over time were included in the models. Viral loads and
immunological variables were transformed using 10-based loga-
rithmic whenever appropriate. Analyses were carried out using
SPSS 15.0 software (SPSS Inc. Chicago, IL) and Strata MP 10.0
(Strata Corp., College Station, TX).
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